logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Relapsed malignant pleural mesothelioma: pembrolizumab disappoints

PROMISE-meso trial yields no survival benefit with pembrolizumab over chemotherapy.